Sevabertinib Approved for Advanced Non-Squamous NSCLC
FDA granted accelerated approval to sevabertinib for select HER2-mutated non-squamous NSCLC, requiring precise molecular eligibility while confirmatory studies establish clinical benefit.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.